Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

MD2-IN-1

SKU: orb1223429

Description

MDK7229, also known as MD2-IN-1 is a MD2 (Myeloid differentiation protein 2) inhibitor. MDK7229 has CAS#111797-22-9. For easy communication, we use its last 4 digit of CAS for name. MDK7229 locked the LPS-induced activation of TLR4/MD2 -downstream pro-inflammatory MAPKs/NF-κB signaling pathways. In a rat model with ALI induced by intracheal LPS instillation, administration MDK7229 exhibited significant protective effect against ALI, accompanied by the inhibition of TLR4/MD2 complex formation in lung tissues.

Research Area

Immunology & Inflammation

Images & Validation

Key Properties

CAS Number111797-22-9
MW358.39
Purity>98% (HPLC)
FormulaC20H22O6
SMILESCOc1ccc(cc1OC)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1
TargetMyeloid differentiation protein 2 (MD2)
SolubilityDMSO : 50 mg/mL 139.51 mM; H2O : < 0.1 mg/mL

Bioactivity

In Vivo
Administration of MD2-IN-1 evidently reduces the LPS-induced increase in protein concentrations in BALF. The lung wet/dry weight ratio is markedly higher in the LPS-treated group than the control group, and MD2-IN-1 treatment reduces LPS-induced pulmonary edema. LPS also causes observable lung histopathologic changes, including areas of inflammatory infiltration, hemorrhage, interstitial edema, thickening of the alveolar wall, and lung tissue destruction. These histopathological changes are ameliorated in the MD2-IN-1 treatment group.
In Vitro
Myeloid differentiation protein 2 (MD2) is a co-receptor of TLR4. Among those derivatives, MD2-IN-1 (compound 20) shows the strongest inhibitory effect on LPS-induced expression of both TNF-α and IL-6. Compare to the vehicle, LPS alone largely increases the amount of TLR4/MD2 complex, while pretreatment with MD2-IN-1 inhibits the increase of TLR4/MD2 complex to the vehicle level. SPR analysis shows that MD2-IN-1 exhibits recognizable binding to rhMD2 protein in a dose-dependent manner, with a KD value of 189 μM, while the KD value of xanthohumol binding to MD2 is 460 μM. Pre-treatment with different doses of MD2-IN-1 dose-dependently reduces FITC-LPS binding to MD2 in cell surface membranes, with a 65% inhibition at 10 μM in terms of mean fluorescence intensity. Pretreatment with MD2-IN-1 also dose-dependently blocks LPS-induced MAPK phosphorylation in the MPMs.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

MD2-IN-1 | MDK7229 | MDK 7229 | MDK 7229.

Similar Products

  • MD2-IN-1 [orb1303038]

    99.43% (May vary between batches)

    111797-22-9

    358.39

    C20H22O6

    1 ml x 10 mM (in DMSO), 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

200 mg
500 mg
5 mg
$ 290.00
10 mg
$ 470.00
25 mg
$ 830.00
50 mg
$ 1,190.00
100 mg
$ 1,650.00